Skip to main content
logo
AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
3.010
+0.180 (6.36%)
Aug 4, 2025, 4:00 PM - Market closed

Verve Therapeutics Revenue

AIM ImmunoTech had revenue of $16.00K in the quarter ending March 31, 2025, a decrease of -60.00%. This brings the company's revenue in the last twelve months to $146.00K, down -24.35% year-over-year. In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%.

Revenue (ttm)
$146.00K
Revenue Growth
-24.35%
P/S Ratio
15.81
Revenue / Employee
$6,348
Employees
23
Market Cap
2.31M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024170.00K-32.00K-15.84%
Dec 31, 2023202.00K61.00K43.26%
Dec 31, 2022141.00K6.00K4.44%
Dec 31, 2021135.00K-28.00K-17.18%
Dec 31, 2020163.00K23.00K16.43%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group422.82B
Johnson & Johnson90.63B
Merck & Co.63.62B
AbbVie58.33B
AstraZeneca56.50B
Novartis AG55.19B
Eli Lilly and Company49.00B
Novo Nordisk43.92B
Revenue Rankings

AIM News

More News